Document Detail


Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study.
MedLine Citation:
PMID:  12075254     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Although anticoagulation therapy is accepted for most patients with atrial fibrillation, 2 different strategies exist for management of the cardiac rhythm: atrial fibrillation is allowed to persist while the ventricular rate is controlled; and atrial fibrillation is converted, and an attempt is made to maintain sinus rhythm. METHODS: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study was a randomized clinical trial that compared these 2 strategies. We report the baseline characteristics of the patients enrolled in the AFFIRM Study. RESULTS: More than 7400 patients at more than 200 North American hospitals and clinics qualified for enrollment in the AFFIRM Study. A total of 4060 patients were enrolled in the AFFIRM Study. The average age of patients enrolled was 70 years, with 39% female and 89% white. Hypertension was present in 71%. Coronary artery disease was present in 38%. Echocardiography was performed in 3311 patients, and results showed normal ventricular function in 68% and normal left atrial size in 33%. Most patients with recurrent episodes had symptoms with atrial fibrillation. Approximately one third of patients were enrolled with a first episode of atrial fibrillation. CONCLUSION: The AFFIRM Study enrolled 4060 predominantly elderly patients with atrial fibrillation to compare ventricular rate control with rhythm control. The patients in the AFFIRM Study were representative of patients at high risk for complications from atrial fibrillation, which indicates that the results of this large clinical trial will be relevant to patient care.
Authors:
Related Documents :
11241014 - Atrial and ventricular electromechanical function in 1-ventricle hearts: influence of a...
10573314 - Tolterodine-warfarin drug interaction.
6486024 - Atrial conduction: effects of extrastimuli with and without atrial dysrhythmias.
2511744 - Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after elec...
18593634 - Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute dec...
7777424 - Italian multicenter clinical experience with endocardial defibrillation: acute and long...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  American heart journal     Volume:  143     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-06-20     Completed Date:  2002-07-18     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  991-1001     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use
Aged
Anti-Arrhythmia Agents / therapeutic use*
Anticoagulants / therapeutic use*
Atrial Fibrillation / complications,  drug therapy*,  physiopathology
Calcium Channel Blockers / therapeutic use
Coronary Disease / complications
Echocardiography
Female
Heart Rate / drug effects*,  physiology
Humans
Hypertension / complications
Male
Risk Factors
Ventricular Function
Grant Support
ID/Acronym/Agency:
N01-HC-55139/HC/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Anti-Arrhythmia Agents; 0/Anticoagulants; 0/Calcium Channel Blockers
Comments/Corrections
Comment In:
Am Heart J. 2003 Dec;146(6):E24; author reply E25   [PMID:  14661013 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation.
Next Document:  Intrauterine diagnosis of heterotaxy syndrome.